Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Intracranial CArtography of Cortical Contribution to Respiratory Load Compensation in Epilepsy (ICARE)

13 mai 2026 mis à jour par: Hospices Civils de Lyon

30% of patients with epilepsy suffer from drug-resistant seizures and have a greater risk of premature mortality than the general population. Among all causes of death, the most frequent is SUDEP, for sudden and unexpected death in epilepsy patients. SUDEP typically occurs after a nocturnal seizure, and primarily results from a postictal central respiratory dysfunction in patients with generalized convulsive seizure (GCS), suggesting the critical role of seizure-related impairment of breathing control, and underscoring the importance of monitoring and preventive interventions during the post-ictal phase. Most of patients with drug-resistant seizures demonstrate transient peri-ictal apnea and hypoxemia especially in the aftermath of a GCS. Experimental and clinical data suggest that most SUDEP primarily result from a fatal seizure-related respiratory arrest 5. Apnea was the primary cause of death in several epilepsy models. In patients whose SUDEP had occurred during long-term video-EEG monitoring, we observed fatal postictal central apnea after a nocturnal GCS in all SUDEP. Accordingly, it is currently hypothesized that in a subgroup of patients, repetition of seizures may contribute to chronic alteration of respiratory regulation which may increase the risk of fatal postictal central respiratory arrest.

Central regulation of autonomic function is ensured by the so-called Central Autonomic Network (CAN), which anatomy in humans has primarily been investigated in neuroimaging studies or using intraEEG (iEEG) data in patients with drug-resistant focal epilepsy undergoing presurgical evaluation with intracerebral electrodes. Central regulation of breathing primarily rely on brainstem, especially the preBötzinger complex for rhythm generation and the retrotrapezoid nucleus and dorsal raphe for chemoreception, especially ventilatory response to hypercapnia. However, through an intricated structures connecting these regions, this respiratory signal projects to a network of cortical and subcortical regions mainly including the limbic and sensorimotor cortical areas. Studies in patients undergoing iEEG reinforced the role of limbic and paralimbic structures, with transient central apnea elicited by direct electrical stimulation of amygdala, hippocampus, anterior parahippocampal, and antero-mesial fusiform gyri. However, our group also reported transient hypoxemia could be elicited by cortical direct electrical stimulation outside the temporo-limbic structures, most commonly after stimulation of the perisylvian cortex. Importantly, our group recently showed that involvement of this perisylvian cortex in the epileptogenic zone is a strong risk factor of SUDEP, reinforcing the importance of further studying its integration in the cortical control of respiration.

The involvement of cortical control of ventilation is particularly important to ensure expiratory load compensation, a typical situation after GCS, which is associated with airway obstruction, especially when the face is positioned into the pillow. This cortical component of the physiological response to experimental expiratory loads was investigated in healthy subjects through the study of EEG activity during an expiratory load compensation protocol. Accordingly, EEGs were processed by ensemble averaging expiratory time-locked segments and examined for pre-expiratory EEG potentials, defined as a slow negative shift from the baseline signal preceding expiration, and suggestive of cortical preparation of expiration. Expiratory load compensation was associated with EEG premotor potential presumably involving the supplementary motor area. However, because of the limited spatial resolution of scalp EEG, the organization of cortical neural sources involved in this expiratory load compensation or during response to hypercapnia, especially the interaction between the premotor cortex, the sensorimotor cortical areas and the perisylvian cortex is unknown.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

20

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Rhone
      • Bron, Rhone, France, 69500
        • Service de Neurologie Fonctionne et d'Epileptologie Hôpital Neurologique Pierre WERTHEIMER
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  1. Written informed consent obtained from study subject and ability for study subject to comply with the requirements of the study
  2. Aged 18 to 55 years old
  3. Diagnosis of drug-resistant focal epilepsy, as defined by the International League Against Epilepsy 20
  4. Patients undergoing SEEG as part of presurgical evaluation
  5. At least one SEEG electrode localized in the perisylvian cortex
  6. At least one SEEG electrode localized in the premotor cortex

Exclusion Criteria:

1. Ongoing or chronic respiratory and/or cardiac insufficiency and/or ischemic cardiac disease 2. History of stroke in the last 5 years 3. Intracranial hypertension related to space-occupying lesion in the brain 4. Pregnant, parturient, or breastfeeding women 5. Individuals receiving psychiatric care 6. Individuals deprived of their liberty by judicial or administrative decision 7. Adults subject to legal protection measures (guardianship, curatorship) 8. Individuals not affiliated with a social security scheme or beneficiaries of a similar scheme

-

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Patients with drug-resistant epilepsy

Patients with drug-resistant focal epilepsy, as defined by the International League Against Epilepsy, who undergo SEEG as part of presurgical evaluation of epilepsy.

In addition to SEEG monitoring, the following procedures will be carried out as part of the research:

  • Comprehensive respiratory monitoring
  • Cardio-respiratory monitoring
  • Expiratory load compensation
  • Hypercapnic challenge
  • Questionnaires completion.
Patients will be recruited among adult patients suffering from drug-resistant focal epilepsy who undergo SEEG monitoring at the Epilepsy Department of the Neurological Hospital. The study will be offered to patients during the hospitalization.
In addition to SEEG monitoring, all participants will undergo comprehensive respiratory monitoring in order to collect respiratory data (tidal volume, VE, and respiratory rate) and gas exchange (PETO2 and PETCO2).
In addition to SEEG channels, cardio-respiratory monitoring consisting of pulse oximetry, respiratory efforts (thoracic and abdominal) and EKG recordings will be performed.
Expiratory load compensation will be assessed in the patient's room in the epilepsy monitoring unit. Patients will breathe through a facemask connected in series to a bidirectional pneumotach and a three-way T-shaped valve. The second port on the three-way valve will be open to room air, and third port will be connected to a CE-marked PEEP valve (PEEP 20 valve, Ambu A/S Denmark) allowing to adjust airflow resistance during expiration from 0.15-2.0 kPa (1.5-20 cmH2O). Respired air will be continuously sampled at the mouth and analyzed for fractional concentrations of O2 and CO2.
The patient breathes through the mouth, using a mouthpiece and a nose clip, through a device fitted with a hermetically sealed bag that measures the various parameters of his/her breathing. At the start of the test, the patient breathes ambient air and his or her breathing is measured. Then, after a few minutes, the patient is connected to the bag, breathing in a closed circuit. This causes a gradual increase in carbon dioxide (CO2) in the inspired air. During this time, breathing parameters will be measured and gas exchanges studied with each breath. The test is stopped when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in the event of intolerance.
Caffeine intake Self-report the degree of "breathlessness" during Expiratory load compensation using a visual analogue scale Self-report the degree of "breathlessness

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Cortical localization of pre-expiratory potentials (via SEEG) during HETL (20 cmH₂O) in drug-resistant epilepsy
Délai: Through study completion, an average of 1 year
Localization of SEEG contacts will use the anatomical MRI images performed in clinical routine. Pre-expiratory potentials are defined as a slow negative shift from the baseline signal starting between 2 and 0.5 s before the onset of expiration. Both visual and statistical analyses will be used to conclude on the presence of significant pre-expiratory potentials over each recording contact, using the same approach as the one our group used in the past in another physiological paradigm.
Through study completion, an average of 1 year

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
dentification of cortical SEEG contacts showing pre-expiratory potentials under 10 cmH₂O low expiratory threshold load (LETL) in drug-resistant epilepsy
Délai: Through study completion, an average of 1 year
Will use the same criteria for localization of SEEG contacts and definition of pre-expiratory potentials as for the primary outcome measure.
Through study completion, an average of 1 year
Cortical localization of SEEG contacts exhibiting pre-expiratory potentials during a hypercapnic challenge (HyperCO₂) in patients with drug-resistant epilepsy.
Délai: Through study completion, an average of 1 year
Will use the same criteria for localization of SEEG contacts and definition of pre-expiratory potentials as for the primary outcome measure.
Through study completion, an average of 1 year
Latency (ms) of the pre-expiratory potentials in each condition (HETL, LETL, HyperCO2)
Délai: Through study completion, an average of 1 year
Through study completion, an average of 1 year
Value of hypercapnic ventilatory response (HCVR)* in each condition (HETL, LETL, HyperCO2)
Délai: Through study completion, an average of 1 year
HCVR measures the increase in minute ventilation (VE) induced by an increase of PETCO2 and is a marker of central chemoreception
Through study completion, an average of 1 year
Number of focal to bilateral tonic-clonic seizures during the 18 months preceding the SEEG
Délai: Inclusion visit
SUDEP typically occurs after a nocturnal seizure , and primarily results from a postictal central respiratory dysfunction in patients with generalized convulsive seizure (GCS) , suggesting the critical role of seizure-related impairment of breathing control, and underscoring the importance of monitoring and preventive interventions during the post-ictal phase.
Inclusion visit
Localization of the SEEG contacts included in the epileptogenic zone (EZ)
Délai: Inclusion visit
The EZ corresponds to cortical regions that directly contribute by their abnormal synchronization to seizure initiation and which surgical removal would be required to result in seizure freedom. Its identification, which is the main medical of SEEG monitoring for presurgical evaluation, combines the analysis of all data collected during the SEEG (inter-ictal, seizures and direct electrical stimulations).
Inclusion visit
Current and past mean daily intake of caffeine (mg/day)
Délai: Inclusion visit
Current usual caffeine intake and the one over the last ten years will be assessed by a validated self-survey filled-in at home by the patient and, if needed, the help of the caregiver filled between the inclusion visit and the hospitalization.
Inclusion visit
Respiratory discomfort of the experiment during each condition (HETL, LETL, HyperCO2)
Délai: Immediately after the respiratory challenges.
The degree of "respiratory discomfort" will be self-assessed by the subjects on a visual analog scale (VAS) . The subjects were asked to set the cursor on a 10-cm horizontal line, between the descriptions "no respiratory discomfort" on the left and "intolerable respiratory discomfort on the right.
Immediately after the respiratory challenges.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 septembre 2026

Achèvement primaire (Estimé)

1 octobre 2028

Achèvement de l'étude (Estimé)

1 octobre 2028

Dates d'inscription aux études

Première soumission

6 mai 2026

Première soumission répondant aux critères de contrôle qualité

13 mai 2026

Première publication (Réel)

20 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 mai 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner